The UPS in diabetes and obesity

Simon S Wing

Address: Polypeptide Laboratory, Division of Endocrinology and Metabolism, Department of Medicine, McGill University and the McGill University Health Centre, Montreal, Quebec, H3A 2B2, Canada
Email: Simon S Wing - simon.wing@mcgill.ca

Published: 21 October 2008

BMC Biochemistry 2008, 9(Suppl 1):S6 doi:10.1186/1471-2091-9-S1-S6
This article is available from: http://www.biomedcentral.com/1471-2091/9/S1/S6
© 2008 Wing; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Type 2 diabetes is caused by defects in both insulin signaling and insulin secretion. Though the role of the ubiquitin proteasome system (UPS) in the pathogenesis of type 2 diabetes remains largely unexplored, the few examples present in the literature are interesting and suggest targets for drug development. Studies indicate that insulin resistance can be induced by stimulating the degradation of important molecules in the insulin signaling pathway, in particular the insulin receptor substrate proteins IRS1, IRS2 and the kinase AKT1 (Akt). In addition, a defect in insulin secretion could occur due to UPS-mediated degradation of IRS2 in the β-cells of the pancreas. The UPS also appears to be involved in regulating lipid synthesis in adipocytes and lipid production by the liver and could influence the development of obesity. Other possible mechanisms for inducing defects in insulin signaling and secretion remain to be explored, including the role of ubiquitylation in insulin receptor internalization and trafficking.

Publication history: Republished from Current BioData’s Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).

Protein pathway involvement in disease

Introduction

The global incidence of diabetes mellitus (commonly referred to as diabetes) is increasing at such a rate as to be characterized as an epidemic. This is primarily due to changes in lifestyle that have led to obesity, a major risk factor for diabetes. In both developed and many developing societies, people have become more sedentary, thereby expending fewer calories. They have also adopted diets with greater calories, resulting in a net positive caloric balance stored in the body as fat (reviewed in [1,2]).

Diabetes is a metabolic disorder, the primary manifestation of which is elevated circulating blood glucose levels. Levels of blood glucose are normally maintained within a tight range of around 3.6–6.0 mM. Elevation of blood glucose, such as occurs after a meal, triggers the release of insulin from the β-cells of the islets of Langerhans in the pancreas. The circulating insulin has two major effects. One is to stimulate glucose uptake into cells by promoting the recruitment of a specific isoform of glucose transporter, GTR4 (GLUT4), from intracellular vesicles to the plasma membrane [3]. GTR4 is primarily expressed in skeletal muscle and adipose tissue [4]. Skeletal muscle accounts for the majority of insulin-stimulated glucose disposal after a meal, due to its larger overall mass. The other major effect of insulin is to suppress glucose production by the liver. The production of glucose by the liver is crucial for maintaining blood glucose levels in the fasted state and occurs by the breakdown of glycogen stores. Glucose can also be produced by the liver via de novo synthesis from amino acids and glycerol generated by the break-
down of protein stores in skeletal muscle and fat stores in adipose tissue, respectively (reviewed in [5]).

Although diabetes is best recognized as a disorder of glucose homeostasis, numerous other metabolic abnormalities are concomitant. Insulin is an anabolic hormone and thus stimulates protein synthesis and lipogenesis and inhibits protein degradation and lipolysis in target tissues. Therefore, diabetes is characterized not only by elevated blood glucose, but also by elevated levels of circulating amino acids and free fatty acids (reviewed in [6-8]).

**Classification of diabetes**

Most cases of diabetes fall into one of two categories, which are very distinct in their etiologies and pathogenesis [9]. Type 1 diabetes, which accounts for around 10% of cases in most populations, is due to an autoimmune-mediated destruction of the insulin-producing β-cells in the pancreatic islets of Langerhans. When approximately 80–90% of β-cells are destroyed, diabetes becomes clinically evident and patients require insulin replacement therapy. Although typically occurring in youth (hence formerly called juvenile onset diabetes), type 1 diabetes can also occur in adults.

Type 2 diabetes accounts for the vast majority of the remaining cases of diabetes. This form of diabetes generally arises from the concurrent presence of two defects, insulin resistance, which is due to a defect in insulin signaling in target tissues, and a relative defect in pancreatic insulin secretion. The requirement for a defect in insulin secretion is demonstrated by obese insulin-resistant subjects. These patients do not develop diabetes because they are capable of secreting extremely high levels of insulin, probably by increasing their β-cell mass. Since obesity commonly results in insulin resistance, the worldwide epidemic of obesity has produced a concomitant epidemic of type 2 diabetes. Fat is now known to secrete humoral factors and some of these (e.g. leptin, adiponectin and resistin) can modulate insulin sensitivity; thus, the altered production of these adipokines in obesity could be involved in predisposition to diabetes (reviewed in [10]).

Other, rare forms of diabetes exist. For example, mutations in the insulin receptor can lead to severe insulin resistance and clinical defects such as leprechaunism [11]. Mutations in mitochondrial DNA have also been associated with diabetes [12]. Moreover, certain drugs can induce hyperglycemia or exacerbate pre-existing diabetes, as well as unmask latent forms of this disease.

**Mechanisms of insulin signaling**

Circulating insulin exerts its effects by binding to insulin receptors on target tissues, leading to the activation of multiple signaling pathways (Figure 1) (reviewed in [13]). The insulin receptor is a membrane receptor tyrosine kinase and binding of insulin to this receptor induces a conformational change, which activates the tyrosine kinase activity on the cytoplasmic surface of the cell [14]. This results in both autophosphorylation of the receptor and phosphorylation of other protein molecules. The immediate substrates of the insulin receptor kinase are members of the insulin receptor substrate (IRS) family (reviewed in [15]). These IRS family members vary in their relative importance in different cells and tissues and therefore can mediate specific actions of insulin. Phosphorylation of IRS proteins on tyrosine residues results in the recruitment of signaling molecules to these proteins. This recruitment is typically mediated by phosphotyrosine binding motifs such as SH2 (Src homology 2) domains and a key such signaling molecule is PI3-kinase. Recruitment of PI3-kinase to IRS1 (IRS-1) results in the phosphorylation of membrane phosphoinositides [16], which leads to membrane recruitment and activation of a downstream signaling kinase, AKT1 (Akt). Akt kinase, in turn, phosphorylates other proteins, the identities of which are largely unknown. However, several downstream targets of AKT1 activation have been identified including FRAP (mTOR) [17] and GSK [18], which lead to stimulation of protein [19] and glycogen synthesis, respectively. Ultimately, these changes result in the metabolic effects of insulin as described above.

In cell culture, and importantly during fetal development, insulin is a growth factor. The stimulation of cell proliferation by insulin is mediated through the activation of the Ras-Raf-MAP kinase pathway [20-23]. Activation of this pathway occurs due to the ability of insulin-stimulated IRS1 to bind the GRB2 (Grb2) protein in proliferating cells. This, in turn, recruits and activates the guanine nucleotide exchange factor SOS (Sos), leading to the activation of the Ras-Raf-MAP kinase signaling pathway [20-23].

**Mechanisms of insulin secretion**

Insulin secretion is tightly controlled by levels of circulating glucose and to a lesser extent, amino acids (Figure 2) (reviewed in [24,25]). The ability of pancreatic β-cells to act as a glucose sensor is mainly due to the expression of specific isoforms of the glucose transporter and glucokinase in these cells. β-cells express the GLUT2 (GLUT2) isoform of glucose transporter, which has a Km for glucose transport of 15–20 mM. Thus, glucose flux into these cells is dependent on circulating concentrations of glucose. In addition, the β-cell glucokinase has a Km of around 8 mM, which also allows generation of glucose-6-phosphate to be dependent on ambient glucose levels. Therefore, high levels of glucose generate more glucose-6-phosphate, which, through glycolysis and oxidative phosphorylation, leads to the production of ATP from ADP.
**General scheme of insulin signaling**. Insulin binding to its receptor activates the receptor tyrosine kinase activity. This leads to autophosphorylation of the receptor and recruitment and phosphorylation of insulin receptor substrate (IRS) proteins. Subsequently, other signaling molecules such as PI3-kinase (PI3K) and GRB2 are recruited, which leads to the activation of the Akt signaling pathway (which mediates many metabolic effects) and the MAP kinase pathway (which mediates cell proliferation), respectively. Insulin binding also leads to receptor internalization into endosomes. From endosomes, receptors can recycle back to the plasma membrane or traffic via multivesicular bodies to the lysosome for degradation. Phosphorylated IRS and the IRS-PI3K complex are signaling molecules that can be inactivated by degradation through the ubiquitin proteasome system. Receptor internalization and trafficking between the endosome and lysosome has been shown to be dependent on ubiquitylation for other receptor tyrosine kinases, but the requirement for UBIQ (ubiquitin) in the case of the insulin receptor remains speculative. In some adipocyte cell lines, the ubiquitin protein ligase CBLB (Cbl-b) has been implicated in mediating translocation of the GTR4 (GLUT4) glucose transporter to the plasma membrane via a RHOQ (Tc10)-dependent pathway.
General scheme of insulin secretion. In the β-cells of the pancreas, elevated blood glucose leads to increased levels of intracellular glucose-6-phosphate. Metabolism of the glucose-6-phosphate through glycolysis and mitochondrial metabolism, leads to increased levels of ATP and to lower levels of ADP. This sequentially results in inhibition of an ATP-sensitive K⁺ channel, depolarization of the plasma membrane, activation of a voltage-dependent Ca²⁺ channel, influx of Ca²⁺ and exocytosis of insulin. Mitochondrial metabolism participates in this process, not only by generating ATP, but also by modulating levels of other metabolites (e.g. GTP, cAMP, NADPH, glutamate, malonyl CoA), which might also contribute to glucose-stimulated insulin secretion. The ATP-sensitive K⁺ channel and voltage-dependent Ca²⁺ channel are sites that could be modulated by the ubiquitin proteasome system (UPS). In addition, β-cell survival can be impaired by UPS-mediated degradation of IRS2 in these cells (see text for details).
This increased intracellular ratio of ATP to ADP results in the inhibition of an ATP-sensitive K⁺ channel in the plasma membrane. Decreased efflux of K⁺ leads to depolarization of the plasma membrane, which activates a voltage-dependent Ca²⁺ channel. Ca²⁺ results in exocytosis of insulin-containing secretory granules and the release of insulin into the circulation. The mitochondrial metabolism also generates several other metabolites that appear to be able to stimulate insulin secretion beyond the effects of the adenine nucleotides. Chronic hyperglycemia also stimulates the activation of iNOS knockout mice are more sensitive to insulin and more resistant to diet-induced obesity than wild-type mice [36]. A possible mechanism for these effects is demonstrated by the induction of IRS1 degradation by iNOS and NO in cultured muscle cells [37]. In addition, other cell culture models of insulin resistance, such as osmotic stress or chronic exposure to insulin or IGF1 (IGF-1), have been shown to promote degradation of IRS2 in NIH3T3 cells [32]. IRS1 degradation also occurs upon chronic insulin exposure of CHO cells that overexpress the insulin receptor or IRS1 [31]. The exact mechanisms and proteolytic system(s) responsible for the degradation of IRS proteins in these latter situations remain unknown. Nonetheless, it is clear that degradation of IRS proteins can be a contributing factor in the development of insulin resistance.

Ubiquitylation and insulin resistance
The molecular mechanisms that result in cells becoming resistant to insulin are only beginning to be defined [26]. In cell culture, resistance can occur due to downregulation of insulin receptors. In patients with diabetes, a small number of studies indicate that receptor numbers are decreased in isolated strips of abdominal skeletal muscle [27], but normal in hepatocytes isolated from liver biopsies [28]. More consistent are observations of decreased receptor kinase activity in these samples, measured as the degree of insulin-stimulated tyrosine phosphorylation of the receptor and IRS1 [27,28]. Most of the insulin resistance appears to be due to resistance at signaling molecules downstream of the receptor. For example, in insulin resistant states, IRS1 can become phosphorylated on serine residues [29], reviewed in [30]. This serine phosphorylation is associated with decreased insulin-stimulated tyrosine phosphorylation of IRS1 resulting in the decreased ability of this protein to mediate signaling. Interestingly, IRS activity can also be lowered by degradation. In various cell lines (for example CHO [31], MEF and NIH3T3 [32]), both IRS1 and IRS2 (IRS-2) can be ubiquitylated and degraded by the proteasome. This ubiquitylation appears to be mediated by the proteins SOCS1 and SOCS3 [33], which function as substrate recognition factors in the cullin-RING ligases subset of ubiquitin protein ligases. Overexpression of these proteins stimulates degradation of IRS1 and IRS2 in cultured cells and in mouse liver [33]. The SOCS1 and SOCS3 proteins interact with the von Hippel Landau (VHL) subfamily of cullin-RING ligases and are induced by cytokines [34]. Such induction by inflammatory factors is particularly interesting in light of numerous recent observations suggesting that diabetes and obesity are pro-inflammatory states and that inflammation plays an important role in mediating insulin resistance (reviewed in [35]).

Other studies also support a role for modulation of IRS levels in mediating insulin resistance. For example, nitric oxide (NO) has been implicated in mediating insulin resistance, as iNOS knockout mice are more sensitive to insulin and more resistant to diet-induced obesity than
Ubiquitylation and insulin secretion

In contrast to the role of ubiquitylation in insulin action, the role of the UPS in insulin secretion is less well defined. Inhibitors of the proteasome can acutely enhance glucose-stimulated insulin release from rat islets in culture [50], but appear to have the opposite effect in a mouse stimulated insulin release from rat islets in culture [51]. Inhibitors of the proteasome can acutely enhance glucose-stimulated insulin release from rat islets in culture [50], but appear to have the opposite effect in a mouse stimulated insulin release from rat islets in culture [51]. Inhibitors of the proteasome can acutely enhance glucose-stimulated insulin release from rat islets in culture [50], but appear to have the opposite effect in a mouse stimulated insulin release from rat islets in culture [51]. Inhibitors of the proteasome can acutely enhance glucose-stimulated insulin release from rat islets in culture [50], but appear to have the opposite effect in a mouse stimulated insulin release from rat islets in culture [51]. Inhibitors of the proteasome can acutely enhance glucose-stimulated insulin release from rat islets in culture [50], but appear to have the opposite effect in a mouse stimulated insulin release from rat islets in culture [51]. Inhibitors of the proteasome can acutely enhance glucose-stimulated insulin release from rat islets in culture [50], but appear to have the opposite effect in a mouse stimulated insulin release from rat islets in culture [51]. Inhibitors of the proteasome can acutely enhance glucose-stimulated insulin release from rat islets in culture [50], but appear to have the opposite effect in a mouse stimulated insulin release from rat islets in culture [51].

Ubiquitylation and biological actions of insulin

In previous sections within Protein pathway involvement in disease, the roles of ubiquitylation in modulating factors that could be involved in causing diabetes were discussed. Ubiquitylation also plays various roles in mediating the actions of insulin. As described earlier, insulin has functions other than stimulation of glucose uptake and suppression of gluconeogenesis. Insulin stimulates lipogenesis in fat, as well as the liver, by activating acetyl-CoA carboxylase, the rate-limiting enzyme in fatty acid synthesis [57]. Upon fasting, lipogenesis is inhibited and acetyl-CoA carboxylase is inactivated as a result of low insulin levels, as well as the effects of catecholamines and glucagon. However, acetyl-CoA carboxylase has also been shown to be inactivated by degradation in adipose tissue. Upon fasting, levels of the pseudokinase protein TRIB3 (Tribbles3) increase in murine fat and the protein associates with the ubiquitin protein ligase COP1, thus stimulating the ubiquitylation and degradation of acetyl-CoA carboxylase [58]. Mice overexpressing TRIB3 in adipose tissue are protected from diet-induced obesity.

Fat is normally transported in the blood in esterified form as triglycerides and packaged with protein into lipoprotein particles. Synthesis of these apoprotein constituents of the particle appears to be important in determining the levels of lipoprotein particles and fat circulating in the blood. Apoprotein B48 (apoB48) is the major apoprotein in the VLDL and LDL particles, which are the major circulating forms of lipid in the blood. Like most secreted proteins, apoB48 enters the lumen of the ER following synthesis. However, in human liver carcinoma HepG2 cells, a significant fraction of synthesized apoB48 is exported from the ER lumen to be degraded by the ER-associated degradation pathway [59]. This pathway involves ubiquitylation of the exported proteins and degradation by the proteasome. Interestingly, exposure of the cells to proteasome inhibitors can inhibit degradation of apoB48, resulting in increased secretion of the lipoprotein containing it. Dietary omega-3 fatty acids are known to lower levels of VLDL and, in intestinal explants from gels, this appears to be due to the ability of these fatty acids to stimulate degradation of apoB48 [60].

Insulin is well recognized to be anabolic in skeletal muscle, by stimulating protein synthesis and inhibiting protein degradation. Protein degradation in skeletal muscle is dependent on the UPS. The cellular regulatory mechanisms have actually been best described for IGF1, but these mechanisms are also likely to apply to insulin, as the signaling pathways of these proteins are very similar. IGF1 activates Akt1, which leads to the activation of FRAP (mTor), the translation initiation factor eIF4B and KS6B1 (p70S6) kinase, resulting in the stimulation of protein synthesis [17]. Simultaneously, Akt1 activation leads
to phosphorylation of members of the FOXO transcription factors, which results in their exclusion from the nucleus [61]. Nuclearily localized FOXO transcription factors normally activate the transcription of two important ubiquitin protein ligases, TRI63 (MuRF1) and FBX32 (atrogin-1, MaFBx). In skeletal muscle, the increased expression of these ligases is tightly associated with protein catabolism and inactivation of the genes coding for these proteins in the mouse leads to blunted muscle atrophy [62]. Thus, growth factor-stimulated cytosolic retention of FOXO factors turns off protein degradation.

Increased expression of components of the ubiquitin proteasome pathway has been observed in the muscles of patients in catabolic states [63-66] but not in all situations. This is probably due to the activation of protein expression when the wasting process is initiated and might not be present in very early [67] or late stages of disease. Some of the suppressive effects of insulin might be related to possible interactions between IDE, an enzyme that could degrade insulin, and the proteasome [68].

**Ubiquitin and ubiquitin-like proteins and type 1 diabetes**

As described earlier within the section Protein pathway involvement in disease, type 1 diabetes arises from an immunological destruction of the insulin producing \( \beta \)-cells. Although an environmental trigger is suspected in this disease, a genetic predisposition to type 1 diabetes is well established, with the HLA haplotype the major determinant of risk, although other genes are also involved. It has also been shown that the M55V substitution in the SUMO4 gene is associated with the risk of developing type 1 diabetes [69] (reviewed in [70]). SUMO4 can be conjugated to the IKBA (IkB\( \alpha \)) inhibitor of NF\( \kappa \)B, leading to the inhibition of NF\( \kappa \)B activation. Expression of the M55V variant of SUMO4 in human liver carcinoma HepG2 cells results in a 5.5-fold increase in NF\( \kappa \)B transcriptional activity compared with expression of the wild-type form of this protein [69]. This increased activity can lead to increased cytokine secretion, which could play a role in the immune destruction of the \( \beta \)-cells.

**Disease models, knockouts and assays**

Commonly used animal models of type 2 diabetes include the ob/ob and db/db mice, which are deficient in leptin or the leptin receptor, respectively [71]. Common rat models include the lean (wild-type) and obese (heterozygous) fatty Zucker rats, which possess a leptin receptor mutation and are normoglycemic [72]. Homozygous mutant rats are obese and become diabetic. Although common forms of human obesity are not due to such defects in leptin or its receptor, obese subjects have generally been found to be leptin-resistant. High fat feeding will readily induce obesity and diabetes in C57bl/6 mice and these mice are frequently used as animal models of overfeeding [73]. The laboratories of C.R. Kahn and M. White at Harvard Medical School have been prominent in generating tissue-specific knockouts of the insulin receptor and insulin receptor substrates, respectively. CBLB (Cbl-b)-deficient mice were created by the D. Bowtell laboratory at the Peter MacCallum Cancer Institute. A larger listing of animal models of diabetes has been recently published [74].

**Disease targets and ligands**

As of February 2008, evidence for the involvement of the UPS in the pathogenesis of diabetes remained limited. The downregulation of key signaling molecules such as IRS1, IRS2 and AKT1 (Akt) in insulin resistant states and the potential roles of the SOCS1 and SOCS3 proteins in targeting these signaling molecules to ubiquitin-dependent degradation is clearly intriguing. Similarly, the high glucose stimulated degradation of IRS2, which plays an important role in the survival of the insulin secreting \( \beta \)-cells, is also interesting. Pharmacological inhibition of the ligases responsible for this degradation would be of interest. The increased insulin sensitivity in CBLB (Cbl-b) knockout mice suggests that this ligase could also be a potential target in spite of the lack of evidence that CBLB ubiquitylates and downregulates the insulin receptor.

**New frontiers in drug discovery**

As of February 2008 there were only a limited number of studies implicating the UPS in the pathogenesis of diabetes and obesity. The most striking observations of these investigations are that the UPS has a role in downregulating IRS proteins and thereby contributing to the two main defects in diabetes, insulin resistance and impaired insulin secretion. Reversing these effects could be a novel approach in the treatment of diabetes and might be tested using gene inactivation models of the SOCS1 and SOCS3 proteins. Such establishment of a clear role for these proteins could identify them as targets for drug therapy in the treatment of diabetes. In view of the pervasiveness of the involvement of the UPS in cell signaling and receptor internalization and trafficking, it is likely that many more roles for the UPS in these disorders will be uncovered, leading to novel drug targets. For example, drug inhibition of CBLB (Cbl-b) or of proteins that are involved in downregulation of the insulin receptor via the endosomal lysosomal system would be an interesting approach to explore. The recent developments of large scale screening technologies will hasten the pace of such discoveries. For example, shRNA libraries against UPS genes have been constructed [75] and could be used to screen for alterations in insulin action in cultured cells.
Note added in proof
Recently, Xu et al. described a CUL7 ubiquitin ligase complex that also binds and targets IRS1 for ubiquitination and degradation [76].

List of abbreviations used
EGF: epidermal growth factor; HGF: hepatocyte growth factor; iNOS: nitric oxide synthase; IRS: insulin receptor substrate; LDL: low density lipoprotein; PDGF: platelet derived growth factor; SOCS: suppressor of cytokine signaling; VLDL: very low density lipoprotein.

Competing interests
The author declares that he has no competing interests.

Acknowledgements
Research in the author’s laboratory is funded by the Canadian Institutes of Health Research and by Genome Canada/Genome Quebec and a Chercheur Nationaux salary award from the Fonds de la recherche en santé du Québec.

This article has been published as part of BMC Biochemistry Volume 9 Supplement 1: 2008: Ubiquitin-Proteasome System in Disease Part 2. The full contents of the supplement are available online at http://www.biomedcentral.com/1471-2091/9?issue=S1.

Additional TPdb reviews on the ubiquitin-proteasome system are also available in BMC Biochemistry – see Volume 8 Supplement 1 http://www.biomedcentral.com/1471-2091/8?issue=S1.

References
1. Prentice AM: The emerging epidemic of obesity in developing countries. Int J Epidemiol 2006, 35:93-99.
2. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
3. Satoh S, Nishimura H, Clark AE, Kozuka I, Vanucci SJ, Simpson IA, Quon MJ, Cushman SW, Holman GD: Use of bismannose photolabel to elucidate insulin-regulated GLUT4 subcellular trafficking kinetics in rat adipose cells. Evidence that exocytosis is a critical site of hormone action. J Biol Chem 1993, 268:17820-17829.
4. James DE, Strube M, Mueckler M: Molecular cloning and characterization of an insulin-regulatable glucose transporter. Nature 1989, 338:83-87.
5. Buse JB, Polonsky KS, Burant CF: Type 2 Diabetes Mellitus. In Williams Textbook of Endocrinology 10th edition. Edited by: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS. Philadelphia: Saunders; 2003.
6. Frayn KN, Arner P, Yki-Jarvinen H: Fatty acid metabolism in adipose tissue, muscle and liver in health and disease. Essays Biochem 2006, 42:89-103.
7. Liu Z, Long W, Fryburg DA, Barrett EJ: The regulation of body and skeletal muscle protein metabolism by hormones and amino acids. J Nutr 2006, 136:2125-217S.
8. Saltiel AR, Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
9. Association AD: Diagnosis and classification of diabetes mellitus. Diabetes Care 2006, 29(Suppl 1):S43-48.
10. Trujillo ME, Scherer PE: Adipose tissue-derived factors: impact on health and disease. Endocr Rev 2006, 27:762-778.
11. Krook A, Brunet L, O’Rahilly S: Homozygous nonsense mutation in the insulin receptor gene in infant with leprechaunism. Lancet 1993, 342:277-278.
12. Ballinger SW, Shoﬀner JM, Hedaya EV, Trounce I, Polak MA, Koontz DA, Wallace DC: Maternally transmitted diabetes and deafness associated with a 10.4 kb mitochondrial DNA deletion. Nat Genet 1992, 1:11-15.
13. Taniguchi CM, Emanueli B, Kahn CR: Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006, 7:35-46.
14. Kasuga M, Fujita-Yamaguchi Y, B lithé DL, Kahn CR: Tyrosine-specific protein kinase activity is associated with the purified insulin receptor. Proc Natl Acad Sci USA 1983, 80:2137-2141.
15. Thirone AC, Huang C, Klip A: Tissue-specific roles of IRS proteins in insulin signaling and glucose transport. Trends Endocrinol Metab 2006, 17:72-78.
16. Backer JM, Myers MG Jr, Shoelson SE, Chin DJ, Sun XJ, Miralpeix M, Hu P, Margolis B, Skolnik EY, Schlessinger J, et al.: Phosphatidylinositol 3-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J 1992, 11:3469-3479.
17. Garami A, Zwartkruis FJ, Nobukuni T, Joaquín M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G: Insulin activation of Rheb, a mediator of mTOR/S6K4/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003, 11:1457-1466.
18. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, Bertrand F, Cherqui G, Perret C, Capeau J: Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001, 20:252-259.
19. Andersson LS, Li JB, Rannels SR: Regulation by insulin of amino acid release and protein turnover in the perfused rat hemi-corpus. J Biol Chem 1977, 252:1476-1483.
20. Carel K, Kummer JL, Shubert C, Leitner W, Heidenreich KA, Draznin B: Insulin stimulates mitogen-activated protein kinase by a Ras-independent pathway in 3T3-L1 adipocytes. J Biol Chem 1996, 271:30625-30630.
21. Liang L, Jiang J, Frank SJ: Insulin receptor substrate-1-mediated enhancement of growth hormone-induced mitogen-activated protein kinase activation. Endocrinology 2000, 141:3328-3336.
22. Skolnik EY, Batzer A, Li N, Lee CH, Lowenstein E, Mohammadi M, Margolis B, Schlessinger J: The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 1993, 259:1953-1955.
23. Skolnik EY, Lee CH, Batzer A, Vicentini LM, Zhou M, Daly R, Myers MJ Jr, Backer JM, Ulrich A, White MF, et al.: The SH2/H3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras pathways. EMBO J 1993, 12:2762-2769.
24. MacDonald PE, Joseph JW, Rorsman P: Glucose-sensing mechanisms in pancreatic beta-cells. Philos Trans R Soc Lond B Biol Sci 2005, 360:2211-2225.
25. Wiederkehr A, Wollheim CB: Minireview: implication of mitochon- dria in insulin secretion and action. Endocrinology 2006, 147:2643-2649.
26. Biddinger SB, Kahn CR: From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol 2006, 68:123-158.
27. Goodyear LJ, Giorgino F, Sherman LA, Carey J, Smith RJ, Dohm GL: Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 1995, 95:2195-2204.
28. Caro JF, Ittoop O, Pories WJ, Meelheim D, Flickinger EG, Thomas F, Jenkins M, Silverman JF, Khan A, Peng SG, Sinha MK: Studies on the mechanism of insulin resistance in the liver from humans with noninsulin-dependent diabetes. Insulin action and binding in isolated hepatocytes, insulin receptor structure, and kinase activity. J Clin Invest 1986, 77:249-258.
29. Tasler JF, Gremaux T, van Obbergen E, Le Marchand-Brusset Y, Ser- ine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. J Biol Chem 1994, 269:6051-6057.
30. Lee YH, White MF: Insulin receptor substrate proteins and diabetes. Arch Pharm Res 2004, 27:361-370.
31. Sun XJ, Goldberg JL, Qiao LY, Mitchell JJ: Insulin-induced insulin receptor substrate-1 degradation is mediated by the protease- somedegradation pathway. Diabetes 1999, 48:1359-1364.
32. Rui L, Fisher TL, Thomas J, White MF: Regulation of insulin-insulin-like growth factor-I signaling by proteasome-mediated degradation of insulin receptor substrate-2. J Biol Chem 2001, 276:40362-40367.
33. Rui L, Yuan M, Frantz D, Shoelson S, White MF: SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS-1 and IRS-2. *J Biol Chem* 2002, 277:24394-24398.

34. Kamura T, Sato S, Haque D, Liu L, Kaelin WG Jr, Conaway RC, Conaway JW: The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras-WD repeat, and ankyrin repeat families. *Genes Dev* 1998, 12:2372-2381.

35. Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. *J Clin Invest* 2006, 116:1793-1801.

36. Perreault M, Marette A: Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. *Nat Med* 2001, 7:138-143.

37. Sugita H, Fujimoto M, Yasukawa T, Shimizu N, Sugita M, Yasuhara S, Martyn JA, Kaneki M: Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells. *J Biol Chem* 2005, 280:14203-14211.

38. Tornheim KA, Ahabir A, Ramasamy R, Erickson KL, Goldkorn T: Tumor necrosis factor-(alpha) decreases Akt protein levels in 3T3-L1 adipocytes via the caspase-dependent ubiquitination of Akt. *Endocrinology* 2005, 146:2726-2735.

39. Dentin R, Liu Y, Koo SH, Hedrick S, Vargas T, Heredia J, Yates J 3rd, Mudunuru M, Yau M, Yuan M, Frantz D, Shoelson S, White MF: Inflammation and insulin resistance. *J Clin Invest* 2006, 116:1793-1801.

40. Posner BI: Regulation of insulin receptor kinase activity by endosomal processes: possible areas for therapeutic intervention. *Curr Opin Investig Drugs* 2003, 4:430-434.

41. Hicke L, Dunn R: Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. *Annu Rev Cell Dev Biol* 2003, 19:141-172.

42. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC: E2-Dependent Ubiquitin-Protein Ligase. *Science* 1999, 286:309-312.

43. Waterman H, Katz M, Rubin C, Shiegemann K, Lavi S, Elson A, Jovin T, Yarden Y: A mutant EGF-receptor defective in ubiquitination and endocytosis unveils a role for Grb2 in negative signaling. *Embo J* 2002, 21:303-313.

44. Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY, Park M: Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a trans-activator of translation. *Cell* 2001, 104:389-396.

45. Mori S, Claesson-Welsh L, Okuyama Y, Saito Y: Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a trans-activator of translation. *Cell* 2001, 104:389-396.

46. Vecchione A, Marchese A, Henry P, Rotin D, Morrione A: Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a trans-activator of translation. *Cell* 2001, 104:389-396.

47. Andoniou CE, Thien CB, Langdon WY, Park M: Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. *Cancer Cell* 2003, 3:519-523.

48. Molero JC, Waring SG, Cooper A, Turner N, Laybutt R, Cooney GJ, James DE: Casitas b-lineage lymphoma-deficient mice are protected against high-fat diet-induced obesity and insulin resistance. *Diabetes* 2006, 55:708-715.

49. Lopez-Avalos MD, Duvivier-Kal VF, Xu G, Bonner-Weir S, Sharma A, Weir GC: Evidence for a role of the ubiquitin-proteasome pathway in pancreatic beta-cell apoptosis. *Diabetes* 2006, 55:1233-1231.

50. Kawai T, Darzynkiewicz Z, Finke R: Measurement of DNA content in human islet amyloid polypeptide and contribu-tions to pancreatic beta-cell apoptosis. Cell Death Differ 2007, 14:4515-4523.

51. Kanik NA, Kiraly M, Bates H, Vranic M, Volchuk A, Brumell JH: Ubiquitinated-protein aggregates form in pancreatic beta-cells during diabetes-induced oxidative stress and are regulated by autophagy. *Diabetes* 2007, 56:930-939.

52. Yan FF, Lin CW, Cartier EA, Shyng SL: Role of ubiquitin-proteasome degradation pathway in biogenesis efficiency of (beta)-cell ATP-sensitive potassium channels. *Am J Physiol Cell Physiol* 2005, 289:C1351-1359.

53. Briaud I, Dickson LM, Lingohr MK, McCuaig JF, Lawrence JC, Rhodes CJ: Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells. *J Biol Chem* 2005, 280:2228-2233.

54. Liawantara D, Elliot M, Smith MW, Yan AO, Walters SN, Marino E, McShea A, Grey ST: Nuclear factor-kappaB regulates beta-cell death: a critical role for A20 in beta-cell protection. *Diabetes* 2006, 55:2491-2501.

55. Donaldson WE: Regulation of fatty acid synthesis. *Fed Proc* 1979, 38:2617-2621. PMID: 40828.

56. Qi L, Heredia JF, Alarajos JY, Scrcратon R, Goebel N, Niessen S, Mole C, Röhm R, Konzalamm BN, Bain J, et al.: TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism. *Science* 2006, 312:1763-1766.

57. Fisher EA, Zhou M, Mitchell DM, Wu X, Omura S, Wang H, Goldberg AL, Ginsberg HN: The degradation of apolipoprotein B 100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70. *J Biol Chem* 1997, 272:20427-20434.

58. Levy E, Saphis S, Ziv E, Marette A, Elchely B, Lambert M, Delvin E: Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: impact of dietary n-3 fatty acids. *Diabetes* 1999, 14203-14211.

59. Brunet A, Bonni A, Zigmold Mj, Lin MZJ, Jaoo P, Juo LS, Anderson MJ, Arden KC, Bennis J, Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell* 2002, 96:587-596.

60. Bodine SC, Laret E, Baunheuter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Parano FJ, Na E, Dharmanarjan K, et al.: Identification of ubiquitin ligases required for skeletal muscle atrophy. *Science* 2001, 294:1704-1708.

61. Khal J, Hine AV, Fearon KC, Deang CH, Tisdale MJ: Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. *Int J Biochem Cell Biol* 2005, 37:219-226.

62. Leger B, Cartoni R, Praz M, Lamon S, Deriaz O, Crettenan A, Gobe-let C, Rehner P, Konzalamm BN, Luthi F, Russell AP: Akt signaling through GSK-3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy. *J Physiol* 2006, 576:923-933.

63. Ogawa T, Furochi H, Maneekaa M, Hirasaka K, Onishi Y, Suzzue N, Otsuka M, Akamatsu M, Akima H, Fukunaga T, et al.: Ubiquitin ligase gene expression in healthy volunteers with 20-day bedrest. *Muscle Nerve* 2006, 34:463-469.

64. Tiao G, Hober S, Wang J, Meyer TA, Lauchette FA, Fischer JH, Has-selgren PO: Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. *J Clin Invest* 1997, 99:163-168.

65. Rome S, Clement K, Rabasa-Lhoret R, Loizan E, Poiou C, Barsh GS, Riou JP, Laville M, Vidal H: Microarray profiling of human skeletal muscle reveals that insulin regulates approximately 800 genes during a hyperinsulinemic clamp. *J Biol Chem* 2003, 278:18063-18068.

66. Bennett RG, Fawcett J, Krucer MC, Duckworth WC, Hamel FG: Insulin inhibition of the proteasome is dependent on degradation of insulin by insulin-degrading enzyme. *J Endocrinol* 2003, 177:239-405.

67. Bohren KM, Nadkarni V, Sang JH, Gabbay KH, Owerbach D: A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. *J Biol Chem* 2004, 279:27233-27238.

68. Li M, Guo D, Isales CM, Ezirik DL, Atkinson M, She JX, Wang CY: SUMO wrestling with type 1 diabetes. *J Mol Med* 2005, 83:504-513.

69. Leibel RL: Single gene obesities in rodents: possible relevance to human obesity. *J Nutr* 1997, 127:1908S.

70. Phillips MS, Liu Q, Hammond HA, Dugan Y, Hey Pj, Caskey CJ, Hess JF: Leptin receptor missense mutation in the fatty Zucker rat. *Nat Genet* 1996, 13:18-19.
73. Schreyer SA, Wilson DL, LeBoeuf RC: C57BL/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis. Atherosclerosis 1998, 136:17-24.

74. Chen D, Wang MW: Development and application of rodent models for type 2 diabetes. Diabetes Obes Metab 2005, 7:307-317.

75. Stegmeier F, Rape M, Draviam VM, Nalepa G, Sowa ME, Ang XL, McDonald ER 3rd, Li MZ, Hannon GJ, Sorger PK, et al.: Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature 2007, 446:876-881.

76. Xu X, Sarikas A, Dias-Santagata DC, Dolios G, Lafontant P, Tsai SC, Zhu W, Nakajima H, Nakajima HO, Field LJ, Wang R, Pan ZQ: The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation. Mol Cell 2008, 30(4):403-414.

Publication history
Republished from Current BioData's Targeted Proteins database (TPdb: http://www.targetedproteinsdb.com).